Amplifiers of selection for the Moran process with both Birth-death and death-Birth updating. Dahkki Jakub Svoboda, Soham Joshi, Josef Tkadlec, Krishnendu Chatterjee

Viečča ollesdeavstta

442-B IL-18-enhanced non-activated CAR T-cells for improved metabolic function and therapeutic efficacy Dahkki Carl H June, Joseph A Fraietta, Xiaoling Jin, Saba Ghassemi, Joseph Durgin, Ashwin Sannecy, Nandana Mukherjee, Andre Kelly, Alexander Shestov, Jakub Svoboda, Roddy O’Connor

Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP Dahkki Vincent Ni, Sunita D. Nasta, Stefan K. Barta, Stephen J. Schuster, Elise A. Chong, Jakub Svoboda, Jennifer J.D. Morrissette, Ashley Barlev, Adam Bagg, Salvatore F. Priore, Daniel J. Landsburg

Viečča ollesdeavstta

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECO... Dahkki Catherine Diefenbach, Opeyemi Jegede, Richard Ambinder, Jonathon Cohen, Michael Robertson, Kevin David, Ranjana Advani, Timothy Fenske, Stefan Barta, Neil Palmisiano, Jakub Svoboda, David Morgan, Reem Karmali, Brad Kahl, Stephen M. Ansell

Viečča ollesdeavstta

Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel Dahkki Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Marco Ruella

Viečča ollesdeavstta

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis Dahkki Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, Alan Skarbnik, Bruce D. Cheson, Clive Zent, Jeffrey Pu, Pavel Kiselev, Andre Goy, David Claxton, Krista Isaac, Kaitlin H. Kennard, Colleen Timlin, Daniel Landsburg, Allison Winter, Sunita D. Nasta, Spencer H. Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul Barr, Chaitra S. Ujjani

Viečča ollesdeavstta

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas Dahkki Jakub Svoboda, Steven M. Bair, Daniel J. Landsburg, Sunita Dwivedy Nasta, Sarah J. Nagle, Stefan K. Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Strelec, Elise Chong, Sheryl Mitnick, Terease S. Waite, Cara King, Hatcher Ballard, Matthew Youngman, James Gerson, John P. Plastaras, Amit Maity, Agata M. Bogusz, Stacy S. Hung, Hisae Nakamura, Reza Nejati, Christian Steidl, Megan Lim, Marco Ruella, Stephen J. Schuster

Viečča ollesdeavstta

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States Dahkki Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, Chadi Nabhan

Viečča ollesdeavstta